Therapy of polymyositis and dermatomyositis

Presse Medicale

Volumn 40, Issue 4, 2011, Pages

  Marie, Isabelle ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; ECULIZUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; SUNSCREEN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AEROBIC EXERCISE; ALLERGIC PNEUMONITIS; ALOPECIA; ANTISYNTHETASE SYNDROME; AVASCULAR NECROSIS; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; COMBINATION CHEMOTHERAPY; DERMATOMYOSITIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FACE ERYTHEMA; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MUSCLE INJURY; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PLASMAPHERESIS; POLYMYOSITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REHABILITATION CARE; SECOND CANCER; SHORT SURVEY; SKIN INJURY; SKIN MANIFESTATION; TELANGIECTASIA; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; VOMITING;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL PRODUCTS; COMBINED MODALITY THERAPY; DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; EXERCISE THERAPY; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; POLYMYOSITIS; RECEPTORS, INTERLEUKIN-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953796483     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.12.012     Document Type: Short Survey

References (169)

1. Benveniste O., Squier W., Boyer O., Hilton-Jones D., Herson S. Physiopathologie des myopathies inflamamtoires idiopathiques. Presse Med 2004, 33:1444-1450.
2. Callen J.P. Dermatomyositis. Lancet 2000, 355:53-57.
3. Chérin P., Marie I. Les nouveaux critères diagnostiques et d'évaluation des polymyosites et dermatomyosites. Rev Med Interne 2005, 26:361-367.
4. Dimitri D. Myopathies inflammatoires: diagnostic et classifications. Presse Med 2009, 38:1141-1163.
5. Marie I. Infections au cours des polymyosites et des dermatomyosites. Presse Med 2009, 38:303-316.
6. Marie I. Atteinte pulmonaire au cours des polymyosites et des dermatomyosites: la pneumopathie interstitielle. Presse Med 2006, 35:683-695.
7. Marie I., Hachulla E., Chérin P., Hellot M.F., Herson S., Levesque H., et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005, 53:155-165.
8. Marie I., Hachulla E., Chérin P., Dominique S., Hatron P.Y., Hellot M.F., et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002, 47:614-622.
9. Marie I., Hachulla E., Hatron P.Y., Hellot M.F., Levesque H., Devulder B., et al. Polymyositis and dermatomyositis: short-term and long-term outcome, and predictive factors. J Rheumatol 2001, 28:2230-2237.
10. Marie I., Hatron P.Y., Hachulla E., Wallaert B., Michon-Pasturel U., Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998, 25:1336-1343.
11. Marie I., Hatron P.Y., Levesque H., Hachulla E., Hellot M.F., Michon-Pasturel U., et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999, 78:139-147.
12. Marie I., Lahaxe L., Benveniste O., Delavigne K., Adoue D., Mouthon L., et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010, 162:337-344.
13. Bohan A., Peter J.B. Polymyositis and dermatomyositis I. N Engl J Med 1975, 292:344-347.
14. Bohan A., Peter J.B. Polymyositis and dermatomyositis II. N Engl J Med 1975, 292:403-407.
15. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1998, 16:193-208.
16. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 1986, 19:112-125.
17. Goebels N., Michaelis D., Engelhardt M., Huber S., Bender A., Pongratz D., et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996, 97:2905-2910.
18. Dalakas M.C. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010, 6:129-137.
19. Emslie-Smith A.M., Arahata K., Engel A.G. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989, 20:224-231.
20. Steiner W.R. Dermatomyositis with a report of case which presented a rare anomaly but once described in man. J Exp Med 1903, 6:407-442.
21. O'Leary P.A., Waisman M. Dermatomyositis: a study of 40 cases. Arch Dermatol Syphil 1940, 41:1001-1119.
22. Benbassat J., Gefel D., Larholt K., Sukenik S., Morgenstern V., Zlotnick A. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985, 28:249-255.
23. Bohan A., Peter J.B., Bowman R.L., Pearson C.M. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977, 56:255-286.
24. Carpenter J.R., Bunch T.W., Engel A.G., O'Brien P.C. Survival in polymyositis: corticosteroids and risk factors. J Rheumatol 1977, 4:207-214.
25. Hochberg M.C., Lopez-Acuna D., Gittelsohn A.M. Mortality from polymyositis and dermatomyositis in the United States, 1968-1978. Arthritis Rheum 1983, 26:1465-1471.
26. Medsger T.A., Robinson H., Masi A.T. Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum. 1971, 14:249-258.
27. Riddoch D., Morgan-Hughes J.A. Prognosis in adult polymyositis. J Neurol Sci 1975, 26:71-80.
28. Rose A.L., Walton J.N. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain 1966, 89:747-768.
29. Choy E.H., Hoogendijk J.E., Lecky B., Winer J.B. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005, 3:CD003643.
30. Callen J.P. Dermatomyositis: diagnosis, evaluation and management. Minerva Med 2002, 93:157-167.
31. Choy E.H., Isenberg D.A. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 2002, 41:7-13.
32. DeVere R., Bradley W.G. Polymyositis: its presentation, morbidity and mortality. Brain 1975, 98:637-666.
33. Iorizzo L.J., Jorizzo J.L. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 2008, 59:99-112.
34. Mastaglia F.L., Garlepp M.J., Phillips B.A., Zilko P.J. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003, 27:407-425.
35. Henriksson K.G., Lindvall B. Polymyositis and dermatomyositis 1990: diagnosis, treatment and prognosis. Prog Neurobiol 1990, 35:181-193.
36. Henriksson K.G., Sandstedt P. Polymyositis: treatment and prognosis. A study of 107 patients. Acta Neurol Scand 1982, 65:280-300.
37. Joffe M.M., Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Hicks J.E., et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94:379-387.
38. Troyanov Y., Targoff I.N., Tremblay J.L., Goulet J.R., Raymond Y., Senécal J.L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005, 84:231-249.
39. Etienne S.D., Vandermeersch V., Chosidow O., Vu-Thi-My-Le C., Godeau P., Diquet B., et al. Paramètres pharmacocinétiques de la prednisone et de la prednisolone chez le volontaire sain. Ann Med Interne 1990, 141:507-511.
40. Drake L.A., Dinehart S.M., Farmer E.R., Goltz R.W., Graham G.F., Hordinsky M.K., et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol 1996, 34:824-829.
41. Oddis C.V., Medsger T.A. Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. J Rheumatol 1988, 15:807-811.
42. Clarke A.E., Bloch D.A., Medsger T.A., Oddis C.V. A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 1995, 38:1218-1224.
43. Bohan A. History and classification of polymyositis and dermatomyositis. Clin Dermatol 1988, 6:3-8.
44. Matsubara S., Sawa Y., Takamori M., Yokoyama H., Kida H. Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994, 57:1008.
45. James W.D., Dawson N., Rodman O.G. The treatment of dermatomyositis with hydroxchloroquine. J Rheumatol 1985, 12:1214-1216.
46. Olson N.Y., Lindsley C.B. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989, 16:1545-1547.
47. Woo T.Y., Callen J.P., Voorhees J.J., Bickers D.R., Hanno R., Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984, 10:592-600.
48. Abdallah-Lotf M., Grasland A., Vinceneux P., Sigal-Grinberg M. Regression of cutis calcinosis with diltiazem in adult dermatomyositis. Eur J Dermatol 2005, 15:102-104.
49. Ambler G.R., Chaitow J., Rogers M., McDonald D.W., Ouvrier R.A. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 2005, 32:1837-1839.
50. Harel L., Harel G., Korenreich L., Straussberg R., Amir J. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J Rheumatol 2001, 28:1129-1132.
51. Marco Puche A., Calvo Penades I., Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 2010, 28:135-140.
52. Slimani S., Abdessemed A., Haddouche A., Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 2010, 77:70-72.
53. Bunch T.W. Prednisone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum 1981, 24:45-48.
54. Ng Y.T., Ouvrier R.A., Wu T. Drug therapy in juvenile dermatomyositis: follow-up study. J Child Neurol 1998, 13:109-112.
55. Ramírez G., Asherson R.A., Khamashta M.A., Cervera R., D'Cruz D., Hughes G.R. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum 1990, 20:114-120.
56. Miller J., Walsh Y., Saminaden S., Lecky B.R.F., Winer J.B. Randomised double-blind controlled trial of methotrexate and steoids compared with azathioprine and steroids in the treatment of idiopathic inflamamtory myopathy. J Neurol Sci 2002, 199:S53.
57. Hollingworth P., de Vere Tyndall A., Ansell B.M., Platts-Mills T., Gumpel J.M., Mertin J., et al. Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases. Ann Rheum Dis 1982, 41:557-562.
58. Bunch T.W., Worthington J.W., Combs J.J., Ilstrup D.M., Engel A.G. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980, 92:365-369.
59. Malaviya A.N., Many A., Schwartz R.S. Treatment of dermatomyositis with methotrexate. Lancet 1968, 2:485-488.
60. Arnett F.C., Whelton J.C., Zizic T.M., Stevens M.B. Methotrexate therapy in polymyositis. Ann Rheum Dis 1973, 32:536-546.
61. Giannini M., Callen J.P. Treatment of dermatomyositis with methotrexate and prednisone. Arch Dermatol 1979, 115:1251-1252.
62. Kasteler J.S., Callen J.P. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 1997, 36:67-71.
63. Metzger A.L., Bohan A., Goldberg L.S., Bluestone R., Pearson C.M. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974, 81:182-189.
64. Miller L.C., Sisson B.A., Tucker L.B., DeNardo B.A., Schaller J.G. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992, 35:1143-1149.
65. Sarova-Pinhas I., Siegal T., Turgman J., Braham J. Methotrexate treatment in dermatomyositis. Eur Neurol 1977, 16:149-154.
66. Sokoloff M.C., Goldberg L.S., Pearson C.M. Treatment of corticosteroid-resistant polymyositis with methotrexate. Lancet 1971, 1:14-16.
67. Villalba L., Hicks J.E., Adams E.M., Sherman J.B., Gourley M.F., Leff R.L., et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998, 41:392-399.
68. Zieglschmid-Adams M.E., Pandya A.G., Cohen S.B., Sontheimer R.D. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 1995, 32:754-757.
69. Zieglschmid-Adams M.E., Pandya A., Cohen S.B., Sontheimer R.D. The value of methotrexate in dermatomyositis. J Am Acad Dermatol 1998, 38:130-132.
70. Elovaara I., Apostolski S., van Doorn P., Gilhus N.E., Hietaharju A., Honkaniemi J., et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008, 15:893-908.
71. Gelfand E.W. The use of intravenous immune globulin in collagen vascular disorders: a potentially new modality of therapy. J Allergy Clin Immunol 1989, 84:613-615. [discussion 615-6].
72. Cherin P., Herson S., Wechsler B., Piette J.C., Bletry O., Coutellier A., et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991, 91:162-168.
73. Cherin P., Piette J.C., Wechsler B., Bletry O., Ziza J.M., Laraki R., et al. Intravenous gamma globulin as first-line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994, 21:1092-1097.
74. Jann S., Beretta S., Moggio M., Adobbati L., Pellegrini G. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry 1992, 55:60-62.
75. Lang B.A., Laxer R.M., Murphy G., Silverman E.D., Roifman C.M. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991, 91:169-172.
76. Mastaglia F.L., Phillips B.A., Zilko P.J. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1998, 65:107-110.
77. Sansome A., Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis: four-year review of nine cases. Arch Dis Child 1995, 72:25-28.
78. Dalakas M.C., Illa I., Dambrosia J.M., Soueidan S.A., Stein D.P., Otero C., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
79. Marie I., Hachulla E., Levesque H., Reumont G., Ducrotte P., Cailleux N., et al. Intravenous immunoglobulins as treatment of life-threatening esophageal involvement in polymyositis and dermatomyositis. J Rheumatol 1999, 26:2706-2709.
80. Marie I., Menard J.F., Hatron P.Y., Hachulla E., Mouthon L., Tiev K., et al. Intravenous immunoglobulins for steroid-refractiry esophageal involvement related to polymyositis and dermatomyositis. A series of 73 patients. Arthritis Care Res (Hoboken) 2010, 62:1748-1755.
81. Danieli M.G., Malcangi G., Palmieri C., Logullo F., Salvi A., Piani M., et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002, 61:37-41.
82. Lueck C.J., Trend P., Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991, 54:1007-1008.
83. Qushmaq K.A., Chalmers A., Esdaile J.M., Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000, 27:2855-2859.
84. Reiff A., Rawlings D.J., Shaham B., Franke E., Richardson L., Szer I.S., et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997, 24:2436-2443.
85. Sánchez Román J., Castillo Palma M.J., Ocaña Medina C., Wichmann I., Chinchón Lara I., Segura Ayestarán D.I. The efficacy of cyclosporin in the treatment of myositis. Rev Clin Esp 1995, 195:449-454.
86. Zeller V., Cohen P., Prieur A.M., Guillevin L. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and long-term follow-up of 6 cases. J Rheumatol 1996, 23:1424-1427.
87. Bendtzen K., Tvede N., Andersen V., Bendixen G. Cyclosporin for polymyositis. Lancet 1984, 1:792-793.
88. Ejstrup L. Severe dermatomyositis treated with cyclosporin A. Ann Rheum Dis 1986, 45:612-613.
89. Keen R.W., Gumpel J.M. Cyclosporin A in adult dermatomyositis. Br J Rheumatol 1993, 32:439.
90. Pugh M.T., Collins N.A., Rai A., Hollinrake K., Coppock J.S. A case of adult dermatomyositis treated with cyclosporin A. Br J Rheumatol 1992, 31:855.
91. Danko K., Szegedi G. Cyclosporin A treatment of dermatomyositis. Arthritis Rheum 1991, 34:933-934.
92. Zabel P., Leimenstoll G., Gross W.L. Cyclosporin for acute dermatomyositis. Lancet 1984, 1:343.
93. Vencovský J., Jarosová K., Machácek S., Studýnková J., Kafková J., Bartůnková J., et al. Cyclosporin A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000, 29:95-102.
94. Fujisawa T., Suda T., Nakamura Y., Enomoto N., Ide K., Toyoshima M., et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005, 32:58-64.
95. Kobayashi I., Yamada M., Takahashi Y., Kawamura N., Okano M., Sakiyama Y., et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 2003, 42:371-374.
96. Kotani T., Makino S., Takeuchi T., Kagitani M., Shoda T., Hata A., et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 2008, 35:24-29.
97. Miyake S., Ohtani Y., Sawada M., Inase N., Miyazaki Y., Takano S., et al. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:128-133.
98. Nawata Y., Kurasawa K., Takabayashi K., Miike S., Watanabe N., Hiraguri M., et al. Corticosteroid-resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol 1999, 26:1527-1533.
99. Selva-O'Callaghan A., Labrador-Horrillo M., Muñoz-Gall X., Martínez-Gomez X., Majó-Masferrer J., Solans-Laque R., et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 2005, 14:534-542.
100. Takada K., Nagasaka K., Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005, 38:383-392.
101. Tani K., Tomioka R., Sato K., Furukawa C., Nakajima T., Toyota Y., et al. Comparison of clinical course of polymyositis and dermatomyositis: a follow-up in Tokushima University Hospital. J Med Invest 2007, 54:295-302.
102. Maeda K., Kimura R., Komuta K., Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis?. Scand J Rheumatol 1997, 26:24-29.
103. Bombardieri S., Hughes G.R., Neri R., Del Bravo P., Del Bono L. Cyclophosphamide in severe polymyositis. Lancet 1989, 1:1138-1139.
104. Chwalińska-Sadowska H., Małdykowa H. Polymyositis-dermatomyositis: a 25-year follow-up of 50 patients (analysis of clinical symptoms and signs and results of laboratory tests). Mater Med Pol 1990, 22:205-212.
105. Cronin M.E., Miller F.W., Hicks J.E., Dalakas M., Plotz P.H. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989, 16:1225-1228.
106. Koh E.T., Seow A., Ong B., Ratnagopal P., Tjia H., Chng H.H. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993, 52:857-861.
107. Yamasaki Y., Yamada H., Yamasaki M., Ohkubo M., Azuma K., Matsuoka S., et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007, 46:124-130.
108. Schnabel A., Reuter M., Biederer J., Richter C., Gross W.L. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003, 32:273-284.
109. Sugisaki K., Takeda I., Iwadate H., Kanno T., Nishimaki T., Kasukawa R. Prevention of progression of interstitial lung lesions by early combination therapy with corticosteroids and cyclosporine/cyclophosphamide in two patients with amyopathic dermatomyositis. Fukushima J Med Sci 2002, 48:103-110.
110. Tanaka F., Origuchi T., Migita K., Tominaga M., Kawakami A., Kawabe Y., et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 2000, 39:428-430.
111. Yoshida T., Koga H., Saitoh F., Sakamoto M., Harada M., Yoshida H., et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 1999, 38:733-738.
112. Schnabel A., Reuter M., Gross W.L. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998, 41:1215-1220.
113. Kameda H., Nagasawa H., Ogawa H., Sekiguchi N., Takei H., Tokuhira M., et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005, 32:1719-1726.
114. Bandelier C., Guerne P.A., Genevay S., Finckh A., Gabay C. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. Swiss Med Wkly 2009, 139:41-46.
115. Caramaschi P., Volpe A., Carletto A., Bambara L.M., Biasi D. Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature. Clin Rheumatol 2007, 26:1795-1796.
116. Edge J.C., Outland J.D., Dempsey J.R., Callen J.P. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65-69.
117. Gelber A.C., Nousari H.C., Wigley F.M. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000, 27:1542-1545.
118. Majithia V., Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005, 44:386-389.
119. Pisoni C.N., Cuadrado M.J., Khamashta M.A., Hughes G.R., D'Cruz D.P. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007, 46:516-518.
120. Tausche A.K., Meurer M. Mycophenolate mofetil for dermatomyositis. Dermatology 2001, 202:341-343.
121. Swigris J.J., Olson A.L., Fischer A., Lynch D.A., Cosgrove G.P., Frankel S.K., et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006, 130:30-36.
122. Marie I, Menard JF, Hachulla E, Cherin P, Benveniste O, Tiev K, et al. Infectious complications in polymyositis and dermatomyositis. A series of 279 patients. Semin Arthritis Rheum 2010, doi:10.1016/j.semarthrit.2010.08.003.
123. Rowin J., Amato A.A., Deisher N., Cursio J., Meriggioli M.N. Mycophenolate mofetil in dermatomyositis: is it safe?. Neurology 2006, 66:1245-1247.
124. Boswell J.S., Costner M.I. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008, 58:403-406.
125. Lange U., Piegsa M., Müller-Ladner U., Strunk J. Anti-Jo-1 antibody positive polymyositis: successful therapy with leflunomide. Autoimmunity 2006, 39:261-264.
126. Oddis C.V., Sciurba F.C., Elmagd K.A., Starzl T.E. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999, 353:1762-1763.
127. Shimojima Y., Gono T., Yamamoto K., Hoshi K., Matsuda M., Yoshida K., et al. Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. Clin Rheumatol 2004, 23:262-265.
128. Yamada A., Ohshima Y., Omata N., Yasutomi M., Mayumi M. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr 2004, 163:561-562.
129. Cherin P., Auperin I., Bussel A., Pourrat J., Herson S. Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases. Clin Exp Rheumatol 1995, 13:270-271.
130. Miller F.W., Leitman S.F., Cronin M.E., Hicks J.E., Leff R.L., Wesley R., et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992, 326:1380-1384.
131. Anandacoomarasamy A., Howe G., Manolios N. Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 2005, 44:562-563.
132. Dold S., Justiniano M.E., Marquez J., Espinoza L.R. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 2007, 26:1186-1188.
133. Efthimiou P., Schwartzman S., Kagen L.J. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006, 65:1233-1236.
134. Hengstman G.J., van den Hoogen F.H., Barrera P., Netea M.G., Pieterse A., van de Putte L.B., et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003, 50:10-15.
135. Korkmaz C., Temiz G., Cetinbas F., Büyükkidan B. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology (Oxford) 2004, 43:937-938.
136. Labioche I., Liozon E., Weschler B., Loustaud-Ratti V., Soria P., Vidal E. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford) 2004, 43:531-532.
137. Riley P., McCann L.J., Maillard S.M., Woo P., Murray K.J., Pilkington C.A. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008, 47:877-880.
138. Iannone F., Scioscia C., Falappone P.C., Covelli M., Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006, 33:1802-1804.
139. Sprott H., Glatzel M., Michel B.A. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 2004, 43:524-526.
140. Dastmalchi M., Grundtman C., Alexanderson H., Mavragani C.P., Einarsdottir H., Helmers S.B., et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008, 67:1670-1677.
141. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52:601-607.
142. Marie I. Connectivites et pseudo-connectivites d'origine médicamenteuse et toxique. Les diagnostics difficiles en médecine interne. Éditions Maloine (3e édition); 2008. p. 179-96.
143. Hengstman G.J., De Bleecker J.L., Feist E., Vissing J., Denton C.P., Manoussakis M.N., et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008, 59:159-163.
144. Klein R., Rosenbach M., Kim E.J., Kim B., Werth V.P., Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010, 146:780-784.
145. Eloranta M.L., Barbasso Helmers S., Ulfgren A.K., Rönnblom L., Alm G.V., Lundberg I.E. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007, 56:3112-3124.
146. Marie I., Heliot P., Roussel F., Hervé F., Muir J.F., Levesque H. Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology (Oxford) 2005, 44:1201-1202.
147. Furlan A., Botsios C., Ruffatti A., Todesco S., Punzi L. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine 2008, 75:366-367.
148. Arlet J.B., Dimitri D., Pagnoux C., Boyer O., Maisonobe T., Authier F.J., et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006, 16:334-336.
149. Brulhart L., Waldburger J.M., Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006, 65:974-975.
150. Chiappetta N., Steier J., Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005, 11:264-266.
151. Chung L., Genovese M.C., Fiorentino D.F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763-767.
152. Dinh H.V., McCormack C., Hall S., Prince H.M. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007, 56:148-153.
153. Lambotte O., Kotb R., Maigne G., Blanc F.X., Goujard C., Delfraissy J.F. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005, 32:1369-1370.
154. Mok C.C., Ho L.Y., To C.H. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007, 34:1864-1868.
155. Noss E.H., Hausner-Sypek D.L., Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006, 33:1021-1026.
156. Sultan S.M., Ng K.P., Edwards J.C., Isenberg D.A., Cambridge G. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008, 26:887-893.
157. Frikha F., Rigolet A., Behin A., Fautrel B., Herson S., Benveniste O. Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases. Rheumatology (Oxford) 2009, 48:1166-1168.
158. Gottenberg J.E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005, 64:913-920.
159. Touma Z., Arayssi T., Kibbi L., Masri A.F. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008, 75:334-337.
160. Feist E., Dörner T., Sörensen H., Burmester G.R. Long-lasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 2008, 35:1230-1232.
161. Sem M., Molberg O., Lund M.B., Gran J.T. Rituximab treatment of the antisynthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009, 48:968-971.
162. Thompson B., Corris P., Miller J.A., Cooper R.G., Halsey J.P., Isaacs J.D. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 2008, 35:2080-2082.
163. Alexanderson H., Stenström C.H., Jenner G., Lundberg I. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000, 29:295-301.
164. Alexanderson H., Stenström C.H., Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology (Oxford) 1999, 38:608-611.
165. Escalante A., Miller L., Beardmore T.D. Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol 1993, 20:1340-1344.
166. Wiesinger G.F., Quittan M., Aringer M., Seeber A., Volc-Platzer B., Smolen J., et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998, 37:196-200.
167. Wiesinger G.F., Quittan M., Graninger M., Seeber A., Ebenbichler G., Sturm B., et al. Benefit of 6months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 1998, 37:1338-1342.
168. Harris-Love M.O. Safety and efficacy of submaximal eccentric strength training for a subject with polymyositis. Arthritis Rheum 2005, 53:471-474.
169. Marie I., Guglielmino E. Infections opportunistes non tuberculeuses au cours des traitements par les anti-TNFα. Rev Med Interne 2010, 31:353-360.